← Back to Search

Virus Vaccine

Influenza Vaccine for Influenza (FLU-PG Trial)

Phase 1
Waitlist Available
Led By Philip M Grant
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 (year 2)
Awards & highlights

FLU-PG Trial Summary

This trial is investigating the immune response to vaccination in pregnancy.

Eligible Conditions
  • Influenza

FLU-PG Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 (year 2)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 (year 2) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Related Adverse Events (Year 2)
Number of Participants With Related Adverse Events (year 1)
Hemagglutination Inhibition Tests
+1 more

FLU-PG Trial Design

1Treatment groups
Experimental Treatment
Group I: Study PhaseExperimental Treatment1 Intervention
Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Quadrivalent inactivated influenza vaccine (IIV)
2019
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,387 Previous Clinical Trials
17,334,045 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,696 Previous Clinical Trials
6,952,574 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,268 Previous Clinical Trials
5,481,127 Total Patients Enrolled

Media Library

Quadrivalent inactivated influenza vaccine (IIV) (Virus Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03888989 — Phase 1
Influenza Research Study Groups: Study Phase
Influenza Clinical Trial 2023: Quadrivalent inactivated influenza vaccine (IIV) Highlights & Side Effects. Trial Name: NCT03888989 — Phase 1
Quadrivalent inactivated influenza vaccine (IIV) (Virus Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03888989 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Response to Influenza Vaccine During Pregnancy
Philip Grant 2019. "Response to Influenza Vaccine During Pregnancy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03888989.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top